Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores
Axcella’s phase 2a long COVID clinical trial has missed its primary endpoint. But with the study linking the drug to improved fatigue scores versus placebo, the biotech plans to meet with regulators ...
IT Leaders Summit debates the true purpose of endpoint security. At the Computing IT Leaders Summit, an audience of some of the UKs top CIOs gathered to listen to experts drawn from a broad range of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback